Beximco Pharmaceuticals (LSE:BXP) Debt-to-Equity : 0.16 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Beximco Pharmaceuticals Debt-to-Equity?

Beximco Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £39.2 Mil. Beximco Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £10.8 Mil. Beximco Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was £312.9 Mil. Beximco Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beximco Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

LSE:BXP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16 Med: 0.26 Max: 0.46
Current: 0.16

During the past 13 years, the highest Debt-to-Equity Ratio of Beximco Pharmaceuticals was 0.46. The lowest was 0.16. And the median was 0.26.

LSE:BXP's Debt-to-Equity is ranked better than
63.2% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs LSE:BXP: 0.16

Beximco Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Beximco Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Debt-to-Equity Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.46

0.32

0.21

0.31

0.24

Beximco Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.28	0.27	0.24	0.17	0.16

Competitive Comparison of Beximco Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Debt-to-Equity falls into.

Beximco Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beximco Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(54.275	+	17.175)	/	294.104
	=	0.24

Beximco Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(39.214	+	10.799)	/	312.891
	=	0.16

Beximco Pharmaceuticals (LSE:BXP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beximco Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (LSE:BXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » Debt-to-Equity

Traded in Other Exchanges

R2WA:Germany BXPHARMA:Bangladesh

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.